BioNTech Acquires Biotheus to Boost Oncology Pipeline

TL;DR

BioNTech just bought Biotheus to get more cancer drugs.

AI Summary

On February 3, 2025, BioNTech SE announced the successful acquisition of Biotheus, a clinical-stage biotechnology company focused on developing novel antibody-based therapies. This strategic move aims to expand BioNTech's oncology pipeline.

Why It Matters

This acquisition strengthens BioNTech's position in the oncology market by integrating Biotheus's promising antibody technologies, potentially leading to new cancer treatments.

Risk Assessment

Risk Level: low — The filing is a routine announcement of a completed acquisition, with no immediate negative financial or operational implications disclosed.

Key Players & Entities

• BioNTech SE (company) — Acquiring company
• Biotheus (company) — Acquired company
• February 3, 2025 (date) — Date of acquisition announcement

FAQ

From the Filing

0001776985-25-000004.txt : 20250203 0001776985-25-000004.hdr.sgml : 20250203 20250203070225 ACCESSION NUMBER: 0001776985-25-000004 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250203 FILED AS OF DATE: 20250203 DATE AS OF CHANGE: 20250203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25580571 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kbiotheusacquisition.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On February 3, 2025, BioNTech SE announced the completion of the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The press release is attached as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: February 3, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Completes Acquisition of Biotheus EX-99.1 2 a99_1250131xbntxpressstate.htm EX-99.1 Document Exhibit 99.1 BioNTech Completes Acquisition of Biotheus • Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers • With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies • Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE)  -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, an